Research in contextEvidence before this studyMetformin is a drug commonly used in the treatment of diabetes and with anticancer activity, which induce YAP phosphorylation to suppress its activity partly through an AMPK-dependent pathway.The value of this studyThis study investigates the anticancer effect of metformin, a drug commonly used for type 2 diabetes. Focusing on lung cancer, we found that metformin has similar effects to the silencing of the oncogene YAP, which is upregulated in lung cancer. Therefore, we hypothesized that the effect of metformin was exerted through YAP. In vitro and in vivo xenografts studies, we demonstrated that metformin inhibits the expression and activity of YAP. At the transcriptional level, we found that metformin interferes with the binding of the transcription factor IRF-1 to YAP promoter. At protein level, we demonstrated the synergistic anticancer effect of metformin and verteporfin in vitro and in vivo.Implications of all the available evidenceWe believe that our study makes a significant contribution to the literature because it highlights the mechanism of action of metformin on the oncogene YAP, and suggests the possible use of metformin, alone or in combination with other drugs, such as verteporfin, for the treatment of lung cancer.Alt-text: Unlabelled Box

1. Introduction {#s0020}
===============

Lung cancer is the leading cause of cancer-related deaths worldwide and classified into two histological subtypes: non-small-cell lung cancer (NSCLC) and small-cell lung cancer \[[@bb0005]\]. NSCLC comprises \~85% of all lung cancers \[[@bb0010]\], and despite various treatment strategies provided to patients, the prognosis remains very poor, with a 5-year survival rate of only 10% to 15% \[[@bb0015]\].

The MST-yes-associated protein (YAP) pathway was first discovered in fruit flies and is involved in regulating cancer, organ development, regeneration, and stem cell biology \[[@bb0020], [@bb0025], [@bb0030], [@bb0035]\]. The core components of this kinase cascade include the kinases MST1/2 and LATS1/2 and the scaffold protein salvador family WW domain-containing protein 1 (SAV1) and MOB1. MST1/2 phosphorylates LATS1/2 via SAV1 in order to subsequently phosphorylate their terminal effectors, including the transcription co-factors YAP and Transcription co-activator with PDZ-binding motif (TAZ) \[[@bb0040]\]. Phosphorylated YAP/TAZ binds to the 14-3-3 protein, leading its retention in the cytoplasm and degradation by the ubiquitin-proteasome pathway. When dephosphorylated, YAP and TAZ translocate into the nucleus and interact with transcription factors, particularly TEA domain family member (TEAD), to induce target gene expression \[[@bb0045]\]. Increased expression and activation of YAP/TAZ are widespread in a broad range of cancers, including lung, liver, colon, ovary, and breast cancers \[[@bb0050],[@bb0055]\]. YAP and TAZ play important roles in cancer initiation, progression, and metastasis \[[@bb0060]\]; therefore, they represent potential drug targets for cancer therapies.

Metformin was originally extracted from *Galega officinalis* and is prescribed as a first-line drug for the treatment of type 2 diabetes \[[@bb0065]\]. Metformin lowers blood glucose by decreasing hepatic gluconeogenesis, inhibiting intestinal glucose adsorption, and increasing peripheral glucose uptake \[[@bb0070]\]. Growing evidence indicates the potential preventive and therapeutic anticancer effects of metformin \[[@bb0075]\]. According to an epidemiological investigation, treatment with metformin might reduce the incidence of cancer in patients with type 2 diabetes \[[@bb0080]\]. Moreover, a recent study showed that metformin use is associated with an almost 20% improvement in overall survival in patients with stage IV NSCLC \[[@bb0085]\]. Similarly, another study confirmed that metformin treatment is related to improved survival in diabetic patients after NSCLC diagnosis \[[@bb0090]\]. However, the potential mechanisms underlying the anticancer effects of metformin remain unclear, and their identification might promote the development of new therapeutic strategies.

Interferon regulatory factors (IRFs) are a group of closely related proteins collectively referred to as the IRF family. IRFs exhibit significant homology in their N-terminal region, which contains a DNA-binding domain (DBD) that includes a cluster of five tryptophan residues. This DBD forms a helix-turn-helix motif and recognizes the interferon-stimulated response element in the promoter of genes targeted by IRFs. The C-terminal region of most IRFs is less conserved and contains an IRF-association domain responsible for homomeric and heteromeric interactions with other proteins, including other IRF family members and non-IRF transcription factors and cofactors \[[@bb0095]\]. IRFs were originally recognized for their role in innate and adaptive immunity, especially in the regulation of interferon-inducible genes \[[@bb0100]\]. Recent research suggests that they are also involved in tumor biology; however, the mechanism through which they promote tumorigenesis remains poorly understood.

In this study, we investigated the role of metformin in relation to YAP in lung cancer. Interestingly, we found that metformin depresses *YAP* promoter activity by competing with the transcription factor IRF-1, thereby inhibiting cell proliferation, migration, invasion, and epithelial-to-mesenchymal transition (EMT) while inducing cell senescence and apoptosis. Our findings provide new insights into the mechanism through which metformin regulates *YAP* expression in the development of lung cancer. Therefore, therapeutic targeting of *YAP* with metformin might represent an effective strategy for the clinical treatment of NSCLC.

2. Materials and methods {#s0025}
========================

2.1. Construction of plasmids {#s0030}
-----------------------------

Myc-tagged YAP, E2F, IRF-1 and IRF-2 constructs were made using the pcDNA 3.1 vector (Invitrogen, Carlsbad, CA, USA). Sequences encoding the Myc epitope (EQKLISEEDL) were added by PCR through replacement of the first Met-encoding codon in the respective cDNA clones. The PCR primers were:

YAP forward primer: 5′-GGGGTACCCCGAGCAGAAACTCATCTCTGAAGAGGATCTGATGGATCCCGGGCAGCAGCCG-3′.

YAP reverse primer: 5′-GCTCTAGAGCCTATAACCATGTAAGAAAGCT-3′.

E2F forward primer: 5′-ATGGCCTTGGCCGGGGCCCCTG-3′.

E2F reverse primer: 5′-TCAGAAATCCAGGGGGGTGAG-3′.

IRF-1 forward primer: 5′-ATGCCCATCACTCGGATGCGC-3′.

IRF-1 reverse primer: 5′-CTACGGTGCACAGGGAATGGC-3′.

IRF-2 forward primer: 5′-ATGCCGGTGGAAAGGATGCGC-3′.

IRF-2 reverse primer: 5′-TTAACAGCTCTTGACGCGGGC-3′.

2.2. Cell lines and culture {#s0035}
---------------------------

Human NSCLC cell lines A549, H1299, Calu6, H520 and the human lung normal control cell line HBEC-3KT (HBEC) were purchased from American Type Culture Collections (Manassas, VA). Cell lines were cultivated in RPMI-1640 medium supplemented with 10% FBS (Hyclone, USA), penicillin/streptomycin (100 mg/ml). Culture flasks were kept at 37 °C in a humid incubator with 5% CO~2~.

2.3. Over-expression and knockdown of genes {#s0040}
-------------------------------------------

The over-expression plasmids (2 μg) or siRNA (1 μg) were transfected into cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) for over-expression or knockdown of YAP, E2F1, IRF-1 or IRF-2, followed by analysis 48--72 h later. The selected sequences for si YAP-1 were: 5′-AA- GGUGAUACUAUCAACCAAA dTdT-3′; siYAP-2 were: 5′-AA- GACATCTTCTGGTCAGAGA dTdT-3′; siIRF-1-1 were: 5′-AA-GUAAUUUCCCUUCCUCAUC dTdT-3′; siIRF-1-2 were: 5′-AA--GUAAGGAGGAGCCAGAAAU dTdT-3′; siIRF-2 were: 5′-AA-GGACCAACAAGGGCAGUGG dTdT-3′; siE2F1 were: 5′-AA- GUGGAUUCUUCAGA. GACAUTT dTdT-3′; and si control were 5′-AA- UUCUCCGAACGUGUCACGU dTdT-3′. These selected sequences were purchased from the company of GenePharma (Shanghai, China).

2.4. Subcellular fraction {#s0045}
-------------------------

Transfected A549 cells were harvested in PBS and resuspended for 10 min on ice in 500 μl CLB Buffer (10 mM Hepes, 10 mM NaCl, 1 mM KH~2~PO~4~, 5 mM NaHCO~3~, 5 mM EDTA, 1 mM CaCl~2~, 0.5 mM MgCl~2~). Thereafter, 50 μl of 2.5 M sucrose was added to restore isotonic conditions. The first round of centrifugation was performed at 6300*g* for 5 min at 4 °C. The pellet washed with TSE buffer (10 mM Tris, 300 mM sucrose,1 mM EDTA, 0.1% NP40, PH 7.5) at 4000 g for 5 min at 4 °C until the supernatant was clear. The resulting supernatant was discarded, and the pellets were nucleus. The resulting supernatant from the first round of differential centrifugation was sedimented for 30 min at 14000 rpm. The resulting pellets were membranes and the supernatant were cytoplasm.

2.5. Western blot analysis {#s0050}
--------------------------

Human lung cancer cells with treatment of metformin were transfected with the relevant plasmids and cultured for 36 h. For western blot analysis, cells were lysed in NP-40 buffer (10 mM Tris pH 7.4, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA pH 8.0, 1 mM EGTA pH 8.0, 1 mM PMSF, and 0.5% NP-40) at 25 °C for 40 mins. The lysates were added to 5× loading dye and then separated by electrophoresis. The primary antibodies used in this study were 1:1000 rabbit anti-Myc (Santa Cruz, Dallas, TX, USA), 1:1000 anti-YAP, anti-pYAP, anti-CTGF and anti-Cyr61 (Cell Signaling Technology, Danvers, MA, USA), 1:1000 anti-E2F1, anti-IRF-2, anti-cytochrome *c*, anti-Bcl-2, anti-Bcl-XL, anti-PARP anti-Vimentin, anti-E-cadherin and anti-cleaved capase-3 (Abcam, Cambridge, UK). The images were obtained through Image Lab™ Software (ChemiDoc™ XRS+, BiO-RAD).

2.6. Immunofluorescent staining {#s0055}
-------------------------------

To examine the protein expressions of YAP, CTGF, Ki67, Vimentin, E-cadherin and Annexin V, lung cancer cells were seeded onto coverslips in a 24-well plate and then transfected with indicated plasmids and treated with metformin for 36 h. Cells were then fixed using 4% formaldehyde for 30 min at 25 °C and treated with 2% bovine serum albumin (BSA) in phosphate buffered saline (PBS) for 30 mins. The coverslips were incubated with rabbit anti-YAP, CTGF, Ki67, Vimentin, E-cadherin and Annexin V monoclonal antibody (Cell Signaling Technology) at 1:200 dilution in 3% BSA. The coverslips were then incubated with an Alexa Fluor 488 (green) and Alexa Fluor 594 (red) tagged anti-rabbit or anti-mouse monoclonal secondary antibody at 1:1000 dilution in 3% BSA. DAPI (3 μg/ml) was added for nuclear counterstaining. Images were obtained with a Zeiss Axio Imager Z1 Fluorescent Microscope (Zeiss, Oberkochen, Germany).

2.7. Cell flow cytometry assays {#s0060}
-------------------------------

A549 cells with indicated treatment were harvested and fixed with 70% ethanol. These cells were then stained using propidium iodide (PI) and the cell cycle stage assessed by flow cytometry. To evaluate apoptosis, cells were cultured at 80% confluence and trypsinized and stained with a PI/Annexin V Apoptosis Detection Kit (Vazyme, Jiangsu Sheng, China). Data were collected and analyzed on a BD FACSC Flow Cytometer using FACSD software (BD Biosciences, San Jose, CA, USA).

2.8. RNA isolation, RT-PCR and RT-qPCR assay {#s0065}
--------------------------------------------

We used Trizol reagent (TransGen Biotech, Beijing, China) to isolate total RNA from the samples and cells. RNA was reverse transcribed into first-strand cDNA using a TransScript All-in-One First-Strand cDNA Synthesis Kit (TransGen Biotech). cDNAs were used in RT-PCR and RT-qPCR assay with the human GAPDH gene as an internal control. The final RT-qPCR reaction mix contained 10 μl Bestar® SYBR Green qPCR Master Mix, Amplification was performed as follows: a denaturation step at 94 °C for 5 mins, followed by 40 cycles of amplification at 94 °C for 30 s, 58 °C for 30 s and 72 °C for 30 s. The reaction was stopped at 25 °C for 5 mins. The relative expression levels were detected and analyzed by ABI Prism 7900HT/ FAST (Applied Biosystems, USA) based on the formula of ^2-ΔΔct^. We got the images of RT-PCR by Image Lab™ Software (ChemiDoc^™^ XRS+, BiO-RAD), and these images were TIF with reversal color format. The RT-PCR and RT-qPCR primers were:

YAP forward primer: 5′-GGATTTCTGCCTTCCCTGAA-3′.

YAP reverse primer: 5′-GATAGCAGGGCGTGAGGAAC-3′.

Cyr61 forward primer: 5′-GGTCAAAGTTACCGGGCAGT-3′.

Cyr61 reverse primer: 5′-GGAGGCATCGAATCCCAGC-3′.

CTGF forward primer: 5′-ACCGACTGGAAGACACGTTTG-3′.

CTGF reverse primer: 5′-CCAGGTCAGCTTCGCAAGG-3′.

E-cadherin forward primer: 5′-ACCATTAACAGGAACACAGG-3′.

E-cadherin reverse primer: 5′-CAGTCACTTTCAGTGTGGTG-3′.

Vimentin forward primer: 5′-CGCCAACTACATCGACAAGGTGC-3′.

Vimentin reverse primer: 5′-CTGGTCCACCTGCCGGCGCAG-3′.

IRF-1 forward primer: 5′-AAAGTCGAAGTCCAGCCGAG-3′.

IRF-1 reverse primer: 5′-CAGAGTGGAGCTGCTGAGTC-3′.

IRF-2 forward primer: 5′-TTTGTATCGGCCTGTGTGAATG-3′.

IRF-2 reverse primer: 5′-AAGCATGGCTGGGACATCA-3′.

E2F1 forward primer: 5′- ATCCCAGCCAGTCTCTACTCA-3′.

E2F1 reverse primer: 5′- AGCCCGCAGGCTGCCCATCC-3′.

GAPDH forward primer: 5′-CTCCTCCTGTTCGACAGTCAGC-3′.

GAPDH reverse primer: 5′-CCCAATACGACCAAATCCGTT-3′.

2.9. Colony forming assay {#s0070}
-------------------------

For colony formation assay, A549 cells with indicated treatment were added to growth medium in RPMI-1640 medium supplemented with 10% FBS (Hyclone, USA), penicillin/streptomycin (100 mg/ml). Culture flasks were kept at 37 °C in a humid incubator with 5% CO~2~. Cells were fed with 1 ml of medium every three days. The colonies were stained with 0.01% crystal violet and counted in 2--3 weeks. The results were observed under an optical microscope (IX53; Olympus) and assessed using the Image J software.

2.10. SA-β-gal staining {#s0075}
-----------------------

SA-β-gal was detected using the Senescence β-Galactosidase Staining kit (C0602; Beyotime) following the manufacturer\'s instructions: In brief, the cells were washed twice with PBS and then fixed with PBS containing 2% formaldehyde and 0.2% glutaraldehyde for 10 mins. The cells were then incubated at 37 °C for 12 h with staining solution. After being washed twice with PBS, the SA-β-gal-positive cells were observed under an optical microscope (IX53; Olympus) and assessed using the Image J software.

2.11. MTT and CCK8 assays {#s0080}
-------------------------

Cell viability was determined using 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) and CCK8 assays in 96-well plates in a manner similar to that previously described for the CCK8 assays. Cells were transfected with indicated plasmids 48 h and with indicated treatment, followed by incubation with MTT and CCK8 for 4 h. Next 100 μl dimethyl sulfoxide was added to dissolve the formazan crystals for the MTT assay. Absorbance was read at 570 nm for MTT and 450 nm for CCK8 using a spectrophotometer (Tecan, Männedorf, Switzerland). Cell viability was calculated as relative absorbance compared to a DMSO-only control.

2.12. luciferase reporter assay {#s0085}
-------------------------------

To construct the core region of YAP promoter, the region of YAP was amplified by PCR from the human cDNA of A549 cells and were inserted into the upstream of the pGL3-Basic vector (Promega, Madison, WI, USA) via *Kpn*I and *Xho*I sites to generate YAP luc. Thereafter, we use the Firefly Luciferase Reporter Gene Assay Kit (Beyotime, RG005) to detect the promoter activities. The PCR primers were:

YAP forward primer: 5′-GGTACCCATCAATGCCGGCTCA-3′.

YAP reverse primer: 5′-CCGCTCGAGTCCCTCCAACTCC-3′.

2.13. CHIP assay {#s0090}
----------------

ChIP experiments were performed according to the laboratory manual. Immunoprecipitation was performed for 6 h or overnight at 4 °C with specific antibodies. After immunoprecipitation, 45 μl protein A-Sepharose and 2 μg of salmon sperm DNA were added and the incubation was continued for another 1 h. Precipitates were washed sequentially for 10 min each in *TSE* I (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 150 mM NaCl), TSE II (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 500 mM NaCl), and buffer III (0.25 M LiCl, 1% NP-40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris- HCl, pH 8.1). Precipitates were then washed three times with TE buffer and extracted three times with 1% SDS, 0.1 M NaHCO3. Eluates were pooled and heated at 65 °C for at least 6 h to reverse the formaldehyde cross-linking. DNA fragments were purified with a QIAquick Spin Kit (Qiagen, CA). For PCR, 1 μl from a 50 μl extraction and 21--25 cycles of amplification were used. We got the images of PCR by Image Lab™ Software (ChemiDoc^™^ XRS+, BiO-RAD), and these images were TIF with reversal color format. The sequences of the primers used are provided as follows:

YAP forward primer: 5′-CTCTTGTTTTCCAGTGTTG-3′.

YAP reverse primer: 5′-AGGGGTGAAAGAACTCCAT-3′.

2.14. Wound healing assays {#s0095}
--------------------------

To assess the cellular migration, 10^4^ cells were seeded onto 6-well plates with transfection of the relevant plasmids. These cells were then incubated in 5% CO~2~ at 37 °C for 48 h. A wound was scraped into the cells using a plastic 200 μl tip and then washed by PBS. The cells were then incubated in DMEM containing 10% FBS. Images were captured at the time points of 0 and 36 h after wounding. The relative distance of the scratches was observed under an optical microscope (IX53, Olympus, Tokyo, Japan) and assessed using the Image J software.

2.15. Transwell invasion assays {#s0100}
-------------------------------

Transwell invasion assays were performed using a 24-well chamber (Costar 3422; Corning Inc., Corning, NY, USA). The lower and upper chambers were partitioned by a polycarbonate membrane (8-μm pore size). Lung cancer cells (1 × 10^3^) were seeded into DMEM without FBS in the upper chamber. DMEM containing 10% FBS was added to the lower chamber. The cells were allowed to migrate for 36 h at 37 °C in a humidified atmosphere containing 5% CO~2~. Cells remaining on the upper side of the membrane were removed using PBS-soaked cotton swabs. The membrane was then fixed in 4% paraformaldehyde for 20 min at 37 °C and then stained with crystal violet. Cells on the lower side of the membrane were counted under an Olympus light microscope (Olympus, Tokyo, Japan) and assessed using the Image J software.

2.16. Measurement of superoxide production {#s0105}
------------------------------------------

The O^2--^ dependent oxidation in A549 cells treated with 1 μM Mito-CP or co-treated with 1 μM Mito-CP and 2 μg YAP in the presence of 7800 units/ml catalase was detected spectrophotometrically at 486--575 nm with a dual wavelength spectrophotometer (Tecan, Männedorf, Switzerland). The experiment process and parameters were described in MitoSOX™ Red mitochondrial superoxide indicator (M36008, Invitrogen, US).

2.17. UV-visible absorption spectral measurements {#s0110}
-------------------------------------------------

The UV-visible absorption spectra were recorded to investigate the extracellular interaction between DNA and metformin using UV-visible spectrophotometer and 1-cm quartz cuvette (T60, PG Instruments Ltd., Leicestershire, UK). The UV-visible absorption spectra of DNA in the presence of metformin was measured in the range of 240 nm--300 nm at room temperature described in the Khajeh et al. \[[@bb0105]\].

2.18. Fluorescence polarization--based peptide displacement assay {#s0115}
-----------------------------------------------------------------

This assay is designed based on the concept that binding of a fluorescein-labeled peptide to a larger molecule, such as a nucleic acid, results in a higher fluorescence polarization (FP) signal that will decrease upon displacement of the peptide by small molecules. The Kdisp values were calculated using the four parameters logistic equation using GraphPad. The equation is as follows:$$P = P_{\min} + \left( {P_{\max}–P_{\min}} \right)/\left( {1 + \left( {X/K_{\text{disp}}} \right)\hat{}H} \right)$$where P stands for polarization; P~min~, minimum polarization; P~max~, maximum polarization; and H, Hill slope. The N-terminal IRF-1 labeled with fluorescein isothiocyanate (FITC) (N-IRF-1) was purified in A549 cells. The metformin/IRF-1 response element of the YAP was synthetized (Sangon, Shanghai, China) and the compound binding assays were performed in a 10 μl volume at a constant concentration of 3.0 × 10^−5^ mol/L. The assay buffer was 20 mM Tris, pH 8.8, 50 mM NaCl, and 0.01% Triton X-100. FP assays were performed in 384-well plates using a Synergy 4 microplate reader (Tecan, Männedorf, Switzerland). An excitation wavelength of 485 nm and an emission wavelength of 528 nm were used. The experiment process and parameters were described in Senisterra G. et al. \[[@bb0110]\].

2.19. Human lung cancer specimen collection {#s0120}
-------------------------------------------

All the human lung cancer and normal lung specimens were collected in Affiliated Hospital of Binzhou Medical College with written consents of patients and the approval from the Institute Research Ethics Committee.

2.20. Analysis of publicly available datasets {#s0125}
---------------------------------------------

To analyze correlation between Yap expression level and prognostic outcome of patients, Kaplan-Meier survival curves of NSCLC patients with low and high expression of YAP were generated using Kaplan-Meier Plotter ([www.kmplot.com/analysis](http://www.kmplot.com/analysis){#ir0005}) \[[@bb0115]\].

2.21. In vivo experiments {#s0130}
-------------------------

To assess the in vivo effects of metformin, 3 to 5-week old female BALB/c athymic (NU/NU) nude mice were housed in a level 2 biosafety laboratory and raised according to the institutional animal guidelines of Binzhou Medical University. All animal experiments were carried out with the prior approval of the Binzhou Medical University Committee on Animal Care. For the experiments, mice were injected with 5 × 10^6^ lung cancer cells and randomly divided into two groups (five mice per group) after the diameter of the xenografted tumors had reached approximately 5 mm. Xenografted mice were then administrated with PBS or metformin (orally, 250 mg/kg  per day), and tumor volume and body weight were measured every second day. For the in vivo study of the synergistic effects of metformin and YAP inhibitor VP, BALB/c mice (n = 10) were also provided a daily oral dose of \~250 mg/kg metformin or injected with Verteporfin (5 mg/Kg) individually or combined use these two drugs. Tumor volume was estimated as 0.5 × a^2^ × b (where a and b represent a tumor\'s short and long diameter, respectively). Mice were euthanized after six weeks of treatment and the tumors were measured at a final time. Tumors were then collected from xenograft mice and analyzed by immunohistochemistry and Western blot.

2.22. Feeding experiment {#s0135}
------------------------

The female BALB/c athymic (NU/NU) nude mice were kept under the standard laboratory conditions of the animal facilities of Binzhou Medical University Hospital in a temperature (22 ± 2 °C) and humidity (45% to 50%) controlled room. In order to investigate the synergistic effects of metformin and YAP inhibitor VP, the mice (n = 10) were divided into four groups and provided an individual daily oral dose of \~250 mg/kg metformin or injected with Verteporfin (5 mg/Kg) or combined use these two drugs three times a week. Their food intake was detected (measured by weighing the consumption of food for mice) at 6 h after treatment mentioned above.

2.23. Immunohistochemical analysis {#s0140}
----------------------------------

Tumor tissues were fixed in 4% paraformaldehyde overnight and then embedded in paraffin wax. Four-micrometer thick sections were stained using hematoxylin and eosin (H&E) for histological analysis according to the laboratory manual.

2.24. Combined index (CI) of drug assay {#s0145}
---------------------------------------

The combined index of drug interaction (CI) was used to analyze the synergistically inhibitory effect of drug combinations. CI is calculated as follows: CI = AB/(AXB). According to the absorbance of each group, AB is the ratio of the combination groups to the control group; A or B is the ratio of the single agent groups to the control group. Thus, a CI value less than, equal to or \>1 indicates that the drugs are synergistic, additive or antagonistic, respectively. CI \<0.7 indicate that the drugs are significantly synergistic.

2.25. Small molecule microarray {#s0150}
-------------------------------

ChemBank molecular library (<http://chembank.broad.harvard.edu>) is a public, web-based informatics environment developed through a collaboration between the Chemical Biology Program and Platform at the Broad Institute of Harvard and MIT. The selected sequences (−56\~−7), which includes the IRF-1/metformin-response element within YAP promoter, were synthetized from the company of GenePharma (Shanghai, China). Typically, each small molecule of ChemBank molecular library in the detection board was mixed with the DNA element (10 μM), which is amine-modified at the 5′ end and allows to produce detection signal. The mixture was concentrated in vacuo. The vials containing the mixtures were irradiated at 365 nm for 1 h with a Super-light model then re-dissolved in MeOH and analyzed with a Perkin--Elmer SCIEX API 2000 pneumatically assisted electrospray triple-quadrupole mass spectrometer equipped with a Hewlett--Packard Series 1100 HPLC system column: 200 mm × 2 mm PEGASIL ODS column (Senshu Scientific Co., Ltd. Tokyo, Japan). The detailed methods of screening for molecular library and data were analyzed in the small molecule microarray according protocols described previously in Seiler and Dominik \[[@bb0120],[@bb0125]\].

2.26. Mass spectrometry conditions {#s0155}
----------------------------------

Single-stranded oligonucleotides of YAP promoter (−56\~−7) were purchased from Sangon (Beijing, China). Oligonucleotides were dissolved in water and synthetized for duplex DNA then desalted for three times. A haloform reaction was used to synthesize the building blocks that contained two to four heterocycle rings, these building blocks were then joined by means of the DCC/HOBt coupling reaction to produce the polyamides. Polyamides were dissolved with methanol/100 mm ammonium acetate (20:80, v/v) to a final volume of 40 ml. These mixtures were incubated with the ChemBank molecular library and then adsorbed and eluted with methanol. Mass spectrometry experiments were performed on a high-resolution quadrupole orbitrap tandem mass spectrometer with a heated electrospray (HESI) probe (Q-Exactive, Thermo Fisher Scientific, Waltham, MA). The ESI source parameters were as follows (positive/negative ion mode): sheath gas 40/45, auxiliary gas 11/10, auxiliary gas heater temperature 220 °C, spray voltage 3.5/−3.2 kV, Capillary temperature 350 °C. Alternating full MS scan and MS/MS scans were 1 implemented in both PRM and AIF assays. The detailed experiment process and parameters were described in Gao, et al. \[[@bb0130]\].

2.27. Ethics statement {#s0160}
----------------------

The experimental protocol was approved by the Research Ethics Committee of Binzhou Medical University, China (No. 2017-014-01 for human lung cancer specimen and No. 2017-004-09 for mouse experiments in vivo) and the written informed consent was obtained from all subjects. Informed consent was obtained from all individual participants included in the study.

2.28. Statistical analysis {#s0165}
--------------------------

Each experiment was repeated at least three times. The statistical analyses of the experiment data were performed by using a two-tailed Student\'s paired *t*-test and one-way ANOVA. Statistical significance was assessed at least three independent experiments and the P-value \<0.05 was considered statistically significant and highlighted an asterisk in the figures, while P-values \<0.01 were highlighted using two asterisks and P-values \<0.001 highlighted using three asterisks in the figures.

3. Results {#s0170}
==========

3.1. Aberrant activation of YAP in lung tumors is associated with adverse prognosis {#s0175}
-----------------------------------------------------------------------------------

A total of 60 samples were obtained from patients who underwent lung-resection surgery at the Affiliated Hospital of Binzhou Medical College (Binzhou, China) between January 2015 and January 2017. Each sample was examined, with the clinicopathologic findings summarized in [Table 1](#t0005){ref-type="table"}. We first examined *YAP* expression in lung tissues from patients with NSCLC by reverse transcription polymerase chain reaction (RT-PCR), western blot, RT-qPCR, and immunohistochemistry. [Fig. 1](#f0005){ref-type="fig"}a through d shows that YAP mRNA and protein levels were elevated in NSCLC tissues as compared with levels in normal adjacent lung tissues analyzed by RT-PCR ([Fig. 1](#f0005){ref-type="fig"}a), western blot ([Fig. 1](#f0005){ref-type="fig"}b), RT-qPCR ([Fig. 1](#f0005){ref-type="fig"}c), and immunohistochemical staining of frozen sections ([Fig. 1](#f0005){ref-type="fig"}d). Additionally, we confirmed that YAP mRNA and protein levels in a panel of NSCLC cell lines, including A549, H1299, Calu6, and H520 cells, was significantly higher than that in normal HBEC cells ([Fig. 1](#f0005){ref-type="fig"}e--h). The expression of two YAP-specific downstream target genes, *connective tissue growth factor* (*CTGF*) and *cysteine-rich angiogenic inducer 61* (*Cyr61*), was also increased in the NSCLC cell lines ([Fig. 1](#f0005){ref-type="fig"}e--g), indicating that *YAP* was hyperactivated, whereas the phosphorylation level of YAP was lower in NSCLC cells as compared with controls cell HBEC ([Fig. 1](#f0005){ref-type="fig"}g and j). Consistently, YAP protein was observed primarily in the nucleus in NSCLC cells as compared with in the cytosol in HBEC cells according to immunofluorescence staining ([Fig. 1](#f0005){ref-type="fig"}h and j) and western blot ([Fig. 1](#f0005){ref-type="fig"}i) analysis. Publicly available datasets (<http://www.kmplot.com/analysis/index.php?p=service&cancer=lung>, 2015 version) \[[@bb0115],[@bb0135],[@bb0140]\] were screened to analyze prognostic correlations between *YAP* expression and the survival of patients with lung cancer. Kaplan--Meier analysis indicated that elevated YAP expression inversely correlated with overall survival (OS; p = 1.1e − 0.9 according to the log-rank test for significance; n = 1926) ([Fig. 1](#f0005){ref-type="fig"}k). These results indicated that YAP expression and activity correlate with NSCLC.Table 1Patient\'s demographics and tumor characteristics and association of YAP level with clinicopathological features in lung cancer population.Table 1CharacteristicsNo. of patients, N = 60 (%)P valuePatients parameter Age (years)0.152 Average \[range\]55 \[30--81\] \<5520 (33.3) ≥5540 (66.7) Gender0.0581 Male35 (58.3) Female25 (41.7)Tumor Characteristics Tumor size (cm)0.006[⁎⁎](#tf0010){ref-type="table-fn"} \<412 (20.0) ≥448 (80.0) Differentiation0.056[⁎](#tf0005){ref-type="table-fn"} Poor40 (66.7) Well-moderate20 (33.3) Lymph node metastasis0.004[⁎⁎](#tf0010){ref-type="table-fn"} N-26 (43.3) N+34 (56.7) Distant metastasis0.008[⁎⁎](#tf0010){ref-type="table-fn"} M-28 (46.7) M+32 (53.3)Level of YAP Protein levelN = 35 ([Fig. 1](#f0005){ref-type="fig"}B) High29 (83.0)0.001[⁎⁎](#tf0010){ref-type="table-fn"} Median3 (8.5)0.031[⁎](#tf0005){ref-type="table-fn"} Low3 (8.5)0.142 mRNA levelN = 35 ([Fig. 1](#f0005){ref-type="fig"}A) High30 (85.7)0.001[⁎⁎](#tf0010){ref-type="table-fn"} Median3 (8.5)0.033[⁎](#tf0005){ref-type="table-fn"} Low2 (5.8)0.157[^2][^3][^4]Fig. 1Aberrant activation of *YAP* in lung tumors is associated with adverse prognosis.a-d the mRNA and protein expression of YAP was detected by RT-PCR (a), western blot (b), RT-qPCR (c) and immunohistochemistry of frozen sections (d) in NSCLC tissues and their normal adjacent lung tissues. GAPDH and α-tubulin served as loading control respectively. e-g RT-PCR (e), RT-qPCR (f) and western blot (g) were used to assess mRNA and protein levels of YAP and its target genes, CTGF and Cyr61, and phosphorylation level of YAP in multiple NSCLC cell lines and normal control cells HBEC. h Immunofluorescence of stained YAP demonstrating increased total protein levels, as well as increased nuclear YAP localization, in both A549 and H1299 lung cancer cells relative to a normal HBEC cell line. i Subcellular localization of YAP was examined using western blot. j the phosphorylation level of YAP was analyzed by immunofluorescent staining in the HBEC, A549 and H1299 cells. k Kaplan-Meier overall survival (OS) curves for YAP expression (n = 1926, p = 1.1e-0.97 using a log-rank test of significance). Results were presented as mean ± SD, and the error bars represent the SD of three independent experiments. (\*\*p \< 0.01 vs control group correspond to two--tailed Student\'s tests).Fig. 1Fig. 2YAP is involved in lung cancer-cell proliferation, apoptosis, migration, invasion, and EMT.A549 cells were knockdown of YAP by using siRNA or overexpressed by using Myc-YAP. a, b the mRNA and protein levels of YAP were analyzed by RT-PCR, western blot (a) and RT-qPCR (b) assay. c the cellular proliferation was analyzed by CCK8 and MTT assay. d the protein of Ki67 was analyzed by immunofluorescent staining. e the Edu staining cells were analyzed by immunofluorescent staining. f the protein of cleaved Caspase3 was analyzed by immunoblotting assay. g the protein of Annexin V was analyzed by immunofluorescent staining. h Colony formation density was analyzed by colony formation assay. i Cell senescence was analyzed by SA-β-gal staining. j Cellular migration ability was analyzed by cell scratch assay. k Cellular invasion ability was analyzed by transwell assay. l the expression of E-cadherin and Vimentin were analyzed by RT-PCR, western blot and RT-qPCR assay. m Statistical analysis of the protein level of YAP and E-cadherin/Vimentin based on Western blot assay (n = 20). n the relationship between protein expression levels of YAP with E-cadherin/Vimentin was analyzed based on western blot assay in A549 cells. Results were presented as mean ± SD, and the error bars represent the SD of three independent experiments. (\*p \< 0.05, \*\*p \< 0.01, ANOVA with Bonferroni correction).Fig. 2Fig. 3Metformin inhibits YAP activity in lung cancer cells.a-d The A549 (a, c) and H1299 (b, d) cells were treated with indicated concentration of metformin. The mRNA and protein level of YAP, p-YAP, CTGF and Cyr61 were analyzed by RT-qPCR and western blot assay. e-h The A549 (e, g) and H1299 (f, h) cells were treated for indicated time of 10 mM metformin. The mRNA and protein level of YAP, p-YAP, CTGF and Cyr61 were analyzed by RT-qPCR and western blot assay. i The A549 and H1299 cells were treated with indicated concentration of metformin for 60 h. The luciferase activity of YAP was analyzed by luciferase reporter assay. j The A549 and H1299 cells were treated with metformin 10 mM for 60 h. The protein of YAP was analyzed by immunofluorescent staining. k Subcellular localization of YAP was examined using western blot. Results were presented as mean ± SD, and the error bars represent the SD of three independent experiments. (\*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, ANOVA with Bonferroni correction).Fig. 3Fig. 4Metformin attenuates *YAP* promoter activity by interfering with IRF-1 binding.a the activities of different fragments of YAP promoter (pGL3-basic, pGL3-1300, pGL3-310, pGL3-185 and pGL3-185Δ) were measured by luciferase reporter gene assays in A549 cells. b the activities of pGL3-185 (−90\~+95) were measured by luciferase reporter gene assays in A549 cells with treatment of the indicated concentration of metformin. c Putative metformin/IRF-1 interacted site in the sequences of YAP. d the UV-visible absorption spectra of DNA in the presence of metformin was measured in the 260 nm at room temperature. e the UV-visible absorption spectra of increasing concentration of DNA in the presence of metformin was measured in the range of 240 nm −300 nm at room temperature. f Schematic diagram depicting the potential transcription factors in the promoter region −400\~−90 and −90\~+95 of YAP by bioinformatics. g The A549 cells were transfected with IRF-1 or siIRF-1. The mRNA and protein levels of IRF-1 were analyzed were analyzed by RT-PCR, immunoblotting and Rt-qPCR assay. h Luciferase activity of A549 cells transfected with plasmids carrying a wild-type or mutant promotor of YAP, in response to IRF-1 or siIRF-1. i the activities of pGL3-185 (−90\~+95) were measured by luciferase reporter gene assays in A549 cells with transfection with the indicated concentration of IRF-1 or siIRF-1. j Quantitative ChIP analysis demonstrating that knockdown of IRF-1 using the siRNA decreases but overexpressing IRF-1 increases IRF-1 levels within the −90/+95 region of YAP promoter in A549 or H1299 cells. k RT-PCR and Western blot result shows that IRF-1 dose-dependently and time- dependently increased the mRNA and protein level of YAP. l RT-PCR and Western blot result shows that IRF-1 increased the mRNA and protein level of the YAP target genes, CTGF and Cyr61. m IRF-1 interacts with the promoter of YAP only when metformin is not existed. IRF-1 proteins were expressed in A549 cells with or without treatment of metformin, and the RNA pulldown assay was carried out using YAPluc Wt or YAPluc Mut as the baits. Precipitated protein was visualized by western blotting using anti-IRF-1 and anti-tubulin antibodies. Tubulin was detected as a control. The amounts of RNA baits used are visualized by ethidium bromide staining. n A549 cells were transfected with IRF-1 and then treated with or without metformin. Luciferase activity of YAP were analyzed with luciferase reporter gene assay in A549 cells. Results were presented as mean ± SD, and the error bars represent the SD of three independent experiments. (\*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, ANOVA with Bonferroni correction).Fig. 4Fig. 5Metformin inhibits cell proliferation, arrests cell cycle progression, and promotes cell senescence and apoptosis in lung cancer cells.The A549 cells were treated with indicated concentration of metformin for 60 h. a the cellular proliferation was analyzed by CCK8 and MTT assay. (\*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, ANOVA with Bonferroni correction). b the protein of Ki67 was analyzed by immunofluorescent staining. (\*\*p \< 0.01 vs control group correspond to two--tailed Student\'s tests). c Colony formation density was analyzed by colony formation assay. (\*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, ANOVA with Bonferroni correction). d Cell cycle profile was analyzed by cell flow cytometry. (\*\*p \< 0.01 vs control group correspond to two--tailed Student\'s tests). e Cell senescence was analyzed by SA-β-gal staining. (\*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, ANOVA with Bonferroni correction). f the protein of cleaved Caspase3 was analyzed by immunoblotting assay. g the protein of Annexin V was analyzed by immunofluorescent staining. h the apoptosis was analyzed by cell flow cytometry. i Cellular invasion ability was analyzed by cell transwell assay. (\*\*p \< 0.01 vs control group correspond to two--tailed Student\'s tests). j, k the expression of E-cadherin and Vimentin were analyzed by RT-PCR, western blot (j) and immunofluorescent staining (k). Results were presented as mean ± SD, and the error bars represent the SD of three independent experiments.Fig. 5Fig. 6Metformin interferes with YAP-mediated NSCLC initiation, progression, and metastasis.a A549 cells were transfected with YAP or YAPS127A, then treated with PBS or metformin 10 mM for 60 h. The cellular proliferation was analyzed by CCK8 assay. b--h A549 cells were transfected with YAP or si YAP, then treated with PBS or metformin 10 mM for 60 h. b the cellular proliferation was analyzed by CCK8 assay. c the protein of Ki67 was analyzed by immunofluorescent staining. d Colony formation density was analyzed by colony formation assay. e Cell senescence was analyzed by SA-β-gal staining. f Cellular migration ability was analyzed by cell scratch assay. g Cellular invasion ability was analyzed by cell transwell assay. h the expressions of E-cadherin and Vimentin were analyzed by RT-PCR, Western blot and RT-qPCR assay. Results were presented as mean ± SD, and the error bars represent the SD of three independent experiments. (\*p \< 0.05, \*\*p \< 0.01, ANOVA with Bonferroni correction).Fig. 6Fig. 7Verteporfin synergistically augments the effects of metformin on YAP function in lung cancer cells.a, b A549 and H1299 cells were incubated with verteporfin and metformin at various concentrations for 24, 48, and 72 h. Cell viability was assessed (%). c the synergistically inhibitory effect of metformin and verteporfin were analyzed by combined index (CI) in A549 and H1299 cells. d-j A549 cells were treated with metformin at 10 mM, verteporfin at 3.5 μM or co-treated with metformin and verteporfin for 60 h. d the protein and mRNA expressions of YAP and its target genes, CTGF and Cyr61, were analyzed by western blot, RT-PCR and RT-qPCR assays. e the protein of Cyr61 was analyzed by immunofluorescent staining. f the cellular proliferation was analyzed by CCK8 and MTT assay. g Colony formation density was analyzed by colony formation assay. h Cellular invasion ability was analyzed by cell transwell assay. i the protein of cleaved Caspase3 was analyzed by immunoblotting assay. j Apoptosis was analyzed by cell flow cytometry. Results were presented as mean ± SD, and the error bars represent the SD of three independent experiments. (\*\*p \< 0.01, ANOVA with Bonferroni correction).Fig. 7Fig. 8Metformin inhibits the in vivo growth of in situ pulmonary xenografts.a the tumor sizes and body weights of nude mice by treatment with control and metformin. b Overall tumor sizes and growth curves. c Kaplan-Meier overall survival (OS) curves of mice treated with control and metformin. d--j H&E microscopy of tumor nodules from primary A549 cells by treatment with control and metformin. d Immunohistochemical staining shows that Ki67, YAP, CTGF, Cyr61 and Vimentin expression was decreased in xenograft tumor tissues after treatment with metformin. However, the E-cadherin expression was increased. Statistical analysis (n = 15) of the protein level of Ki67 (e), YAP (f), CTGF (g), Cyr61 (h), Vimentin (i) and E-cadherin (j). (\*\*p \< 0.01 vs control group and NS (not significant; P \> 0.05) correspond to two--tailed Student\'s tests). k, l the body weight (k) and overall tumor sizes (l) of YAP over expression tumor-loaded mouse by treatment with metformin, verteporfin or co-treatment of metformin and verteporfin. (\*\*p \< 0.01, ANOVA with Bonferroni correction). m Kaplan-Meier overall survival (OS) curves of YAP over expression tumor-loaded mouse by treatment with metformin, verteporfin or co-treatment of metformin and verteporfin. n the diagram of the antineoplastic metformin down-regulates YAP through competitive combination with the transcription factor IRF-1 on YAP promotor to disrupts NSCLC progression. Results were presented as mean ± SD, and the error bars represent the SD of three independent experiments.Fig. 8

3.2. YAP is involved in lung cancer-cell proliferation, apoptosis, migration, invasion, and EMT {#s0180}
-----------------------------------------------------------------------------------------------

To investigate the function of YAP in NSCLC cells, we knocked down *YAP* with siRNA (siYAP-1 and siYAP-2) or overexpressed it by transfecting a plasmid encoding Myc-YAP in A549 cells ([Fig. 2](#f0010){ref-type="fig"}a and b; and [Supplementary Fig. 1](#f0045){ref-type="graphic"}a--d). We found that knockdown of YAP using siYAP-2 was better ([Supplementary Fig. 1](#f0045){ref-type="graphic"}a--d), therefor siYAP-2 was used to carry out the experiment for knockdown of YAP. To study and compare the effects of different protein levels of YAP in lung cancer cell properties, we established a control (co-transfection with a pcDNA vector and siRNA control), siYAP (co-transfection of siYAP-2 and a pcDNA vector), and Myc-YAP (co-transfection of pcDNA Myc-YAP and an siRNA control) groups for each experiment. To investigate the role of YAP in cell growth, we performed assays using a Cell counting Kit 8 (CCK8) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), evaluated the rate of Ki-67-positive staining (commonly used as a proliferation index), and performed colony formation assays in A549 cells transfected with siYAP-2 or Myc-YAP. The results showed that the proliferative ability of the cells positively correlated with *YAP* expression levels, with cell-growth-curve analysis confirming this correlation over time ([Fig. 2](#f0010){ref-type="fig"}c). Ki67 expression ([Fig. 2](#f0010){ref-type="fig"}d) and the number of 5-ethynyl-2′-deoxyuridine (Edu)-labeled cells ([Fig. 2](#f0010){ref-type="fig"}e) were elevated among A549 cells transfected with Myc-YAP relative to levels observed in controls, with the opposite results observed in A549 cells following *YAP* knockdown. Western blot analysis of cleaved caspase-3 ([Fig. 2](#f0010){ref-type="fig"}f) and Annexin V-propidium iodide staining ([Fig. 2](#f0010){ref-type="fig"}g) were used to investigate the effect of YAP on apoptosis, revealing that *YAP* silencing promoted apoptosis, whereas *YAP* overexpression inhibited apoptosis in A549 cells. Moreover, *YAP* knockdown decreased colony formation in A549 cells; however, *YAP* overexpression augmented colony formation ([Fig. 2](#f0010){ref-type="fig"}h). Attenuated cell senescence is a common mechanism by which cancer cells avoid death. Here, β-galactosidase staining to detect the role of YAP in cell senescence revealed that *YAP* expression was negatively correlated with cell senescence ([Fig. 2](#f0010){ref-type="fig"}i). We then examined the effect of YAP on cell migration and invasion via scratch and transwell assays, respectively. We found that *YAP* expression was positively associated with the migratory and invasive abilities of A549 cells ([Fig. 2](#f0010){ref-type="fig"}j and k). These data suggested that YAP is critical for the regulation of cancer-cell proliferation, apoptosis, senescence, migration, and invasion. To assess the role of YAP in EMT, we variations in E-cadherin and vimentin levels according to *YAP* status. RT-PCR, western blot, and RT-qPCR analyses showed that *YAP* silencing decreased mRNA and protein levels of vimentin and increased those of E-cadherin, whereas the opposite results were observed upon *YAP* overexpression in A549 cells ([Fig. 2](#f0010){ref-type="fig"}l and m). Furthermore, spearman rank correlation analysis revealed positive correlations between YAP and vimentin levels and negative correlations between YAP and E-cadherin levels ([Fig. 2](#f0010){ref-type="fig"}n). These results indicated that YAP is involved in lung cancer-cell proliferation, apoptosis, migration, invasion, and EMT.

3.3. Metformin inhibits YAP activity in lung cancer cells {#s0185}
---------------------------------------------------------

Because the effects of *YAP* knockdown were similar to cellular responses to metformin, we speculated that the effect of metformin is at least partially exerted through its action on YAP signaling. To determine whether YAP plays a role in responses to metformin, we measured the expression of *YAP* and its target genes following treatment with increasing concentrations of metformin (range: 0--20 mM). In A549 or H1299 cells treated with metformin, YAP mRNA and protein levels, as well as levels of the YAP target genes *CGTF* and *Cyr61*, significantly decreased along with increases in YAP phosphorylation in a dose-dependent manner according to RT-qPCR, western blot ([Fig. 3](#f0015){ref-type="fig"}a--d), and RT-PCR ([Supplementary Fig. 2](#f0050){ref-type="graphic"}a--d) analyses. Similarly, as shown as in the [Fig. 3](#f0015){ref-type="fig"}e--h and [Supplementary Fig. 2](#f0050){ref-type="graphic"}e--h, metformin treatment downregulated *YAP*, *CTGF*, and *Cyr61* expression and enhanced YAP phosphorylation over time, confirming that metformin inactivates YAP in A549 and H1299 cells. We further investigated the effect of metformin on *YAP* promoter activity using a luciferase reporter assay, finding that metformin significantly decreased transcriptional activation of *YAP* in A549 and H1299 cells ([Fig. 3](#f0015){ref-type="fig"}i). Moreover, immunofluorescence staining and western blot analysis demonstrated that metformin decreased YAP levels in the nucleus and increased phosphorylated YAP levels in the cytoplasm of A549 and H1299 cells ([Fig. 3](#f0015){ref-type="fig"}j and k), with YAP consistently found in cytoplasmic extracts from A549 cells treated with metformin and in nuclear extracts from untreated A549 cells ([Fig. 3](#f0015){ref-type="fig"}k). These data indicated that metformin suppressed YAP activity in lung cancer cells by downregulating *YAP* mRNA expression and augmenting YAP phosphorylation, thereby inhibiting YAP nuclear translocation and target gene expression.

3.4. Metformin attenuates YAP promoter activity by interfering with IRF-1 binding {#s0190}
---------------------------------------------------------------------------------

To investigate the effect of metformin on *YAP* expression, we first isolated the core region of *YAP* promoter. Regions of *YAP* promoter (−1050/+105, −400/−90, and −90/+95) were cloned in the pGL3 plasmid to generate pGL3-1300, pGL3-310, and pGL3-185 plasmids, which were used in luciferase reporter assays in A549 cells to determine their activity with the treatment of 10 mM metformin for 60 h. We found pGL3-185 exhibited minimal luciferase activity among the three plasmids ([Fig. 4](#f0020){ref-type="fig"}a), indicating that the −90/+95 region represented the core region of *YAP* promoter reposed to metformin. We then observed that metformin treatment decreased pGL3-185-related luciferase activity in A549 cells in a dose-dependent manner ([Fig. 4](#f0020){ref-type="fig"}b), suggesting that this region of *YAP* promoter might be responsible for metformin-mediated attenuation *YAP* promoter activity. Subsequent deletion of nucleotides at positions −36 to −27 (pGL3-185Δ) in the *YAP* promoter abolished this attenuation ([Fig. 4](#f0020){ref-type="fig"}a and c; and [Supplementary Fig. 3](#f0055){ref-type="graphic"}a) based on this region being identified as a putative metformin-response element (TTTCCTGGA) ([Fig. 4](#f0020){ref-type="fig"}c). Next, we explored whether metformin directly binds this region (−36 to −27, DNAp) using UV-visible absorption spectral measurements. The absorbance value at 260 nm (A260 nm) compared with the concentration ratio of metformin to DNAp \[n(Met)/n(DNAp)\] was used to calculate interactions between metformin and DNAp. The results showed that the ratio of metformin to DNAp was 0.43 at the inflection point of the measurement curve ([Fig. 4](#f0020){ref-type="fig"}d). As shown in [Fig. 4](#f0020){ref-type="fig"}e, upon increasing the DNAp concentration, we observed a gradual quenching of fluorescence intensity along with a slight red shift in the maximum emission wavelength, indicating a direct interaction between metformin and DNAp (TTTCCTGGA). These data confirmed that metformin directly bound the metformin-response element of the *YAP* promoter (−36 to −27).

To identify the mechanism associated with metformin-specific inhibition of *YAP* promoter activity, we analyzed the −90/+95 region using the PROMO platform \[[@bb0145],[@bb0150]\] (<http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promo.cgi?dirDB=TF_8.3>). Interestingly, we found that four transcription factors, including c-Ets-1, c-Ets-2, Elk-1, and IRF-1, could potentially bind this region of the *YAP* promoter ([Fig. 4](#f0020){ref-type="fig"}f). Moreover, we analyzed the −400/−90 region of the *YAP* promoter, the luciferase activity of which was similar to that of the luciferase control ([Fig. 4](#f0020){ref-type="fig"}a). Recent reports indicate that E2F within this region of the *YAP* promoter is modulated by metformin and cooperates with YAP/TEAD2 to promote a cell cycle progression and DNA replication \[[@bb0155],[@bb0160]\]. Therefore, we explored whether E2F could be modulated by metformin to regulate *YAP* expression. Our results showed that the activity of the *YAP* promoter and *YAP* expression were not regulated by E2F in A549 cells ([Supplementary Fig. 4](#f0060){ref-type="graphic"}a--d), indicating that metformin-mediated attenuation of *YAP* promoter activity is independent of E2F. Importantly, we found that three of the transcription factors (c-Ets-1, c-Ets-2, c-Ets-1, and Elk-1) also continued to bind the −400/−90 region of the *YAP* promoter ([Fig. 4](#f0020){ref-type="fig"}f), suggesting that they were not involved in *YAP* promoter activation (i.e., region −90/+95). A previous study reported that IRF-1 upregulation contributes to malignant transformation by regulating genes participating in multiple aspects of human cancer initiation, progression, and metastasis. To identify a relationship between IRF-1, metformin, and the *YAP* promoter, we constructed luciferase reporter plasmids containing either the wild-type *YAP* promoter (−90/+95; YAPluc-Wt) or a *YAP* promoter harboring a mutated version (−36 to −27) of the metformin-response element (YAPluc-Mut) ([Fig. 4](#f0020){ref-type="fig"}c). Additionally, we established *IRF-1* knockdown (siIRF-1-1 and siIRF-1-2) ([Supplementary Fig. 3](#f0055){ref-type="graphic"}b--f) or overexpressing cell lines by transfection of pcDNA-IRF-1 in A549 cells ([Fig. 4](#f0020){ref-type="fig"}g). We found that knockdown of IRF-1 using siIRF-1-2 was better ([Supplementary Fig. 3](#f0055){ref-type="graphic"}b--f), therefore siIRF-1-2 was used to carry out the experiment for knockdown of IRF-1. Co-transfection of A549 cell s with YAPluc-Wt and the *IRF-1*-overexpressing plasmid increased luciferase activity relative to that observed with control plasmids. Similarly, co-transfection with YAPluc-Wt and siIRF-1 decreased the luciferase activity in A549 cells relative to co-transfection with the control plasmid and siRNA. By contrast, luciferase activity did not change in A549 cells co-transfected with YAPluc-Mut and with either status of *IRF-1* ([Fig. 4](#f0020){ref-type="fig"}h). These results suggested that IRF-1 directly targets the *YAP* promoter at the metformin-response element. Moreover, we observed that *IRF-1* overexpression increased luciferase activity associated with the pGL3-185 (−90/+95) region in A549 cells in a dose-dependent manner ([Fig. 4](#f0020){ref-type="fig"}i). Quantitative chromatin immunoprecipitation (ChIP) assays were performed to confirm IRF-1 binding to the −90/+95 region. Consistent with our results, ChIP assays indicated that this region in A549 or H1299 cells overexpressing *IRF-1* promoted IRF-1 binding to this region ([Fig. 4](#f0020){ref-type="fig"}j), increased YAP mRNA and protein levels in a dose- and time-dependent manner ([Fig. 4](#f0020){ref-type="fig"}k; and [Supplementary Fig. 3](#f0055){ref-type="graphic"}g and h), and increased mRNA and protein levels of the YAP target genes *CTGF* and *Cyr61* relative to control cells ([Fig. 4](#f0020){ref-type="fig"}l and [Supplementary Fig. 3](#f0055){ref-type="graphic"}i). The opposite effects were observed upon knockdown of IRF-1 ([Fig. 4](#f0020){ref-type="fig"}l and [Supplementary Fig. 3](#f0055){ref-type="graphic"}j). These data indicated that IRF-1 bound the *YAP* promoter and increased *YAP* transcription and that of its target genes. Evaluation of IRF-2, an IRF-1 homolog, was performed according to reports showing differences in amino acid composition and biological function between IRF-1 and IRF-2 \[[@bb0165],[@bb0170]\]. Importantly, we analyzed the core region of *YAP* promoter using the PROMO platform and we found that IRF-2 did not bind this region of the *YAP* promoter \[[@bb0145],[@bb0150]\] and confirmed that *YAP* expression was not regulated by IRF-2 ([Supplementary Fig. 4](#f0060){ref-type="graphic"}e--h). We then assessed whether competitive binding occurred between metformin and IRF-1 in this region, potentially resulting in IRF-1-mediated inhibition of *YAP* expression and that of its target genes. ChIP assays revealed that IRF-1 bound the *YAP* promoter in the absence of metformin but was undetectable upon treatment of the cells with metformin ([Fig. 4](#f0020){ref-type="fig"}m). To identify whether metformin disrupts IRF-1 interaction with the *YAP* promoter, we firstly detected the effect of metformin on the IFR-1. Our result showed that the expression of IFR-1 was not regulated by metformin by the RT-qPCR ([Supplementary Fig. 4](#f0060){ref-type="graphic"}i) and Western blot assay ([Supplementary Fig. 4](#f0060){ref-type="graphic"}j), which indicated that metformin neither binds to nor regulates the expression of IFR-1 in A549 cells. we then used fluorescein isothiocyanate-labeled IRF-1 (1−120) peptides that included the DNA-binding domain to perform peptide-displacement assays ([Supplementary Fig. 3](#f0055){ref-type="graphic"}k) \[[@bb0110],[@bb0175]\]. After verifying IRF-1 peptide (1--120) binding to the *YAP* promoter ([Supplementary Fig. 3](#f0055){ref-type="graphic"}l), we found that metformin treatment displaced the labeled peptide with a K~disp~ value of 10 ± 2.3 mM ([Supplementary Fig. 3](#f0055){ref-type="graphic"}m), indicating that metformin interfered with IRF-1 binding to the *YAP* promoter. Moreover, we found that metformin treatment abrogated the increased *YAP* promoter activity induced by IRF-1 in A549 cells in a dose-dependent manner ([Fig. 4](#f0020){ref-type="fig"}n). Furthermore, we used the small-molecule microarray, which are collections of small drug molecules arrayed on modified glass slides and provide a fast and inexpensive method for identifying small drug molecules that bind to specific molecules such as protein, DNA, RNA, etc. (24,25), to identify whether metformin directly bind to the IRF-1 response element within the YAP promoter. Our result showed that the wild-type YAP promoter (−90/+95) directly bind to the small molecule of metformin ([Supplementary Fig. 3](#f0055){ref-type="graphic"}n). In addition, mass spectrometry analysis indicated that the eluent achieved from IRF-1 response element contains the small molecule of metformin ([Supplementary Fig. 3](#f0055){ref-type="graphic"}o). These findings indicated that metformin interfered with IRF-1 binding to the *YAP* promoter and inhibited *YAP* expression.

3.5. Metformin inhibits cell proliferation, arrests cell cycle progression, and promotes cell senescence and apoptosis in lung cancer cells {#s0195}
-------------------------------------------------------------------------------------------------------------------------------------------

We then investigated the effect of metformin on several biological processes in A549 cells. CCK8 and MTT assays demonstrated that metformin inhibited cell growth in a dose- and time-dependent manner ([Fig. 5](#f0025){ref-type="fig"}a). A decrease in the number of Ki-67-positive cells was observed in cells treated with metformin ([Fig. 5](#f0025){ref-type="fig"}b), and anchorage-independent colony formation assays showed that the number of A549 colonies decreased upon treatment with metformin in a dose-dependent manner ([Fig. 5](#f0025){ref-type="fig"}c). We further examined the cell cycle distribution of A549 cells treated with metformin by flow cytometry, finding that metformin treatment reduced the proportion of cells in the S phase and enhanced that of cells in the G2 phase ([Fig. 5](#f0025){ref-type="fig"}d). Moreover, A549 cells treated with metformin showed increased cell senescence, as shown by β-galactosidase staining ([Fig. 5](#f0025){ref-type="fig"}e), cleaved caspase-3 ([Fig. 5](#f0025){ref-type="fig"}f) and Annexin V ([Fig. 5](#f0025){ref-type="fig"}g) levels, and apoptosis levels according to flow cytometry ([Fig. 5](#f0025){ref-type="fig"}h). Furthermore, metformin inhibited cell invasion and migration ([Fig. 5](#f0025){ref-type="fig"}i and [Supplementary Fig. 5](#f0065){ref-type="graphic"}a). We then determined whether metformin regulates the expression of E-cadherin and vimentin, finding that metformin treatment upregulated E-cadherin expression, but downregulated vimentin in a dose-dependent manner ([Fig. 5](#f0025){ref-type="fig"}j and k; and [Supplementary Fig. 5](#f0065){ref-type="graphic"}b). These results indicated that metformin treatment inhibited cell proliferation, arrested cell cycle progression, and promoted cell senescence and apoptosis in lung cancer cells.

3.6. Metformin interferes with YAP-mediated NSCLC initiation, progression, and metastasis {#s0200}
-----------------------------------------------------------------------------------------

Our results showed that YAP regulates cell proliferation, apoptosis, and cell senescence ([Fig. 2](#f0010){ref-type="fig"}), and that metformin treatment attenuated YAP activity in lung cancer cells ([Fig. 3](#f0015){ref-type="fig"}, [Fig. 4](#f0020){ref-type="fig"}) and decreased cell proliferation, invasion, migration, and EMT while increasing cell senescence and apoptosis ([Fig. 5](#f0025){ref-type="fig"}). Therefore, we hypothesized that metformin treatment would interfere with YAP-mediated NSCLC initiation, progression, and metastasis in lung cancer and investigated whether YAP downregulation at the transcription level could account for the effect of metformin on the aforementioned processes. Previous reports showed that AMP-activated protein kinase (AMPK) phosphorylation is significantly increased in response to metformin treatment, and that activation of AMPK leads to YAP cytoplasmic retention and S127 phosphorylation \[[@bb0180], [@bb0185], [@bb0190], [@bb0195]\]. Therefore, to evaluate which YAP-inhibitory function dominated in lung cancer cells, we separately transfected A549 cells with plasmids overexpressing YAP or YAPS127A (the continuously activated form of YAP), followed by metformin administration. Our results showed no clear changes in cell growth ([Fig. 6](#f0030){ref-type="fig"}a), Ki-67 staining ([Supplementary Fig. 6](#f0070){ref-type="graphic"}a), cleaved caspase-3 levels ([Supplementary Fig. 6](#f0070){ref-type="graphic"}b), or cell migration ([Supplementary Fig. 6](#f0070){ref-type="graphic"}c) and invasion ([Supplementary Fig. 6](#f0070){ref-type="graphic"}d) between groups, suggesting that the inhibitory effect of metformin on YAP at the transcription level is more important than the phosphorylation status of YAP in A549 cells. Furthermore, we treated *YAP*-knockdown or --overexpressing cells with metformin and observed that lung cancer-cell proliferation significantly increased after *YAP* overexpression, but that this effect was suppressed upon metformin treatment ([Fig. 6](#f0030){ref-type="fig"}a and b; and [Supplementary Fig. 6](#f0070){ref-type="graphic"}e). Additionally, lung cancer-cell proliferation significantly decreased after *YAP* silencing, with this effect augmented by metformin treatment ([Fig. 6](#f0030){ref-type="fig"}b and [Supplementary Fig. 6](#f0070){ref-type="graphic"}e). Similar results were obtained when we investigated the expression of Ki67 ([Fig. 6](#f0030){ref-type="fig"}c), Edu interpolation ([Supplementary Fig. 6](#f0070){ref-type="graphic"}f), colony formation ([Fig. 6](#f0030){ref-type="fig"}d), cell senescence ([Fig. 6](#f0030){ref-type="fig"}e), cell migration ([Fig. 6](#f0030){ref-type="fig"}f), and cell invasion ([Fig. 6](#f0030){ref-type="fig"}g) upon YAP overexpression or silencing and cotreatment them with metformin. Moreover, assessment of E-cadherin and vimentin regulation by YAP following metformin treatment indicated that *YAP* overexpression increased vimentin levels and decreased those of E-cadherin, with the opposite effects observed upon *YAP* silencing. However, metformin treatment decreased the effects of *YAP* overexpression and augmented the effects of *YAP* silencing ([Fig. 6](#f0030){ref-type="fig"}h). Furthermore, recent evidences suggest that metformin inhibits human cancer growth by inducing apoptosis via the mitochondria-mediated pathway \[[@bb0200], [@bb0205], [@bb0210]\] and control of mitochondrial structure and function is regulated by the YAP oncogenic pathway \[[@bb0215],[@bb0220]\]. Basing on these evidences and results mentioned above, we hypothesized that metformin affects mitochondrial structure and function via inhibiting YAP and then restrains human cancer growth. Owing to metformin interferes with YAP-mediated NSCLC initiation, progression, and metastasis ([Fig. 6](#f0030){ref-type="fig"}), therefore *YAP*-knockdown can be used as a substitute for metformin to explore the hypothesis. Our results showed that *YAP*-knockdown and metformin indeed affects the integrity and function of mitochondria and induces the mitochondrial apoptosis analyzed by the proteins of mitochondrial cytC, cytosolic cytC, Bcl-2, Bcl-XL, Bax, PARP in A549 cells ([Supplementary Fig. 7](#f0075){ref-type="graphic"}a--d). The mitochondrial apoptotic pathway ([Supplementary Fig. 7](#f0075){ref-type="graphic"}d) and ROS level ([Supplementary Fig. 7](#f0075){ref-type="graphic"}e) significantly increased after metformin treatment with this effect reversed by Yap overexpression. These results indicated that metformin affects mitochondrial structure and function via inhibiting YAP. Additionally, 3-Carboxy proxyl nitroxide (Mito-CP), the mitochondria-targeted compounds (38), disrupts mitochondrial membrane potential, structure and function ([Supplementary Fig. 7](#f0075){ref-type="graphic"}f) and were co-treated with *YAP-* overexpression to investigate whether YAP influences mitochondrial apoptosis-mediated lung cancer cell growth and apoptosis. We found that combination treatment with Mito-CP and *YAP*- overexpression significantly reversed the ROS level and cell growth relative to that observed following individual treatment with Mito-CP ([Supplementary Fig. 7](#f0075){ref-type="graphic"}f--h). We then explored apoptosis levels and markers by immunoblot of cleaved Caspase-3 and immunofluorescent staining of Annexin V, finding that co-treatment with Mito-CP and *YAP*- overexpression resulted in lower levels of apoptosis than individual treatment with Mito-CP ([Supplementary Fig. 7](#f0075){ref-type="graphic"}i, j). These data suggested that *Yap*-knockdown involved in the transformation of mitochondrial structure and function to inhibit lung cancer cell growth and apoptosis. Collectively, our data indicated that the biological effects of metformin are due, at least in part, to the downregulation of YAP.

3.7. Verteporfin synergistically augments the effects of metformin on YAP function in lung cancer cells {#s0205}
-------------------------------------------------------------------------------------------------------

Verteporfin (VP) inhibits YAP activity by disrupting the interaction between YAP and TEAD and represses the expression of YAP target genes \[[@bb0225],[@bb0230]\]. Because both metformin and VP regulate YAP activity, we investigated whether the combination of these two drugs could exert a synergistic effect in NSCLC cells by examining the expression of the two YAP target genes (*CTGF* and *Cyr61*). Incubation with VP reduced the viability of A549 and H1299 cells in dose- and time-dependent manners, with the IC~50~ of VP 7.8 μM, 3.5 μM, and 1.5 μM for 24 h, 48 h, and 72 h, respectively, whereas that of metformin was 17.4 mM, 12.3 mM, and 7.8 mM, respectively, in A549 cells ([Fig. 7](#f0035){ref-type="fig"}a and b). In H1299 cells, these values were 8.0 μM, 3.7 μM, and 1.8 μM for VP and 18.4 mM, 12.1 mM, and 8.4 mM for metformin for the same respective time periods ([Fig. 7](#f0035){ref-type="fig"}a and b). Therefore, for subsequent experiments assessing the synergistic effects of combination treatment, we used 3.5 μM VP and 10 mM metformin in A549 cells and 4 μM VP and 10 mM metformin in H1299 cells for 48 h. The results showed that the combined index (CI) of metformin and VP was 0.532 in A549 cells and 0.502 in H1299 cells, indicating a synergistic effect in lung cancer cells ([Fig. 7](#f0035){ref-type="fig"}c). We then evaluated this effect on Yap activity in lung cancer cells, revealing that combination treatment with metformin and VP dramatically reduced the expression of *CTGF* and *Cyr61* as compared with treatment with either metformin or VP in A549 cells ([Fig. 7](#f0035){ref-type="fig"}d). The synergistic effect of the two drugs was also shown on YAP target genes, CTGF and Cyr61, by immunofluorescence ([Fig. 7](#f0035){ref-type="fig"}e and [Supplementary Fig. 8](#f0080){ref-type="graphic"}a, b). However, *YAP* expression was only decreased by treatment with metformin, suggesting that metformin reduced YAP transcription, whereas VP interfered with the interaction between YAP and TEADs to reduce YAP target genes expression, which is represented function of YAP at protein level ([Supplementary Fig. 8](#f0080){ref-type="graphic"}c). A549 cell growth in response to metformin and/or VP treatment was examined by CCK8, MTT, and colony formation assays. As shown in [Fig. 7](#f0035){ref-type="fig"}f, combination treatment with metformin and VP significantly reduced cell growth relative to that observed following treatment with either metformin or VP. We obtained similar results upon Ki67 staining ([Supplementary Fig. 8](#f0080){ref-type="graphic"}d), the protein of Vimentin and E-cadherin ([Supplementary Fig. 8](#f0080){ref-type="graphic"}e), colony formation ([Fig. 7](#f0035){ref-type="fig"}g), cell migration ([Supplementary Fig. 8](#f0080){ref-type="graphic"}f) and cell invasion ([Fig. 7](#f0035){ref-type="fig"}h) assays. We then explored apoptosis levels and markers by immunoblot and flow cytometry, finding that co-treatment with metformin and VP resulted in higher levels of apoptosis than individual treatment with either drug ([Fig. 7](#f0035){ref-type="fig"}i and j). These results suggested that combination treatment with metformin and VP synergistically inhibited cell proliferation, promoted apoptosis, and suppressed lung cancer-cell migration/invasion by downregulating YAP.

3.8. Metformin inhibits the in vivo growth of in situ pulmonary xenografts {#s0210}
--------------------------------------------------------------------------

To address the central question regarding whether metformin treatment can delay tumorigenesis in lung cancer, we explored the in vivo antitumor activity of metformin in tumor xenografts assays. Approximately 2 weeks after subcutaneous injection of A549 cells into the concave niche of the cecum of experimental mice, larger tumors were observed in the control group (treated with phosphate-buffered saline) than in the experimental group (treated with metformin) ([Fig. 8](#f0040){ref-type="fig"}a and b), and we did not observe any significant change in the body weight of the animals in the two groups ([Fig. 8](#f0040){ref-type="fig"}a). The group treated with metformin exhibited increased survival ([Fig. 8](#f0040){ref-type="fig"}c), and semi-quantitative immunohistochemical analysis of Ki-67 ([Fig. 8](#f0040){ref-type="fig"}e), YAP ([Fig. 8](#f0040){ref-type="fig"}f), CTGF ([Fig. 8](#f0040){ref-type="fig"}g), Cyr61 ([Fig. 8](#f0040){ref-type="fig"}h), and vimentin ([Fig. 8](#f0040){ref-type="fig"}i) expression in the xenografts revealed that metformin treatment led to lower levels of these proteins as compared with those in the control group ([Fig. 8](#f0040){ref-type="fig"}d; *n* = 15), with opposite results observed for E-cadherin ([Fig. 8](#f0040){ref-type="fig"}d and j). These results indicated that metformin decreased levels of YAP and inhibited the in vivo growth of pulmonary xenografts. Moreover, we confirmed whether co-treatment with metformin and VP synergistically inhibited tumor growth and invasion by downregulating YAP in vivo. Our data showed that the body weight of YAP-overexpressing tumor loaded mice treated with combinations of metformin and VP was higher relative to that in mice receiving metformin treatment alone ([Fig. 8](#f0040){ref-type="fig"}k). The food intake every 3 days was subsequently increased in the group receiving co-treatment with metformin and VP relative to that given to the group treated with metformin alone ([Supplementary Fig. 9](#f0085){ref-type="graphic"}a). These data indicated that the combined use of metformin and VP reduced metformin-specific side effects and possessed the synergistic effects of metformin in vivo. Furthermore, we observed that tumor sizes decreased significantly, and mouse survival increased significantly in the co-treatment group relative to the outcomes observed in groups receiving single treatment and the control group harboring *YAP*-expressing tumors ([Fig. 8](#f0040){ref-type="fig"}l and m). Additionally, we observed that YAP\'s target genes\' CTGF and Cyr61mRNA and protein expression was significantly decreased in xenograft tumor tissue receiving co-treatment relative to that in groups receiving single treatment by analysis of RT-PCR ([Supplementary Fig. 9](#f0085){ref-type="graphic"}b), RT-qPCR ([Supplementary Fig. 9](#f0085){ref-type="graphic"}c, d) and Western blot ([Supplementary Fig. 9](#f0085){ref-type="graphic"}e) assay. Likewise, the similar result of EMT marker protein vimentin but opposite result of E-cadherin was obtained in vivo by analysis of RT-qPCR ([Supplementary Fig. 9](#f0085){ref-type="graphic"}f). These data suggested that co-treatment with metformin and VP synergistically inhibited tumor growth and invasion related to YAP in vivo and in vitro.

4. Discussion {#s0215}
=============

In this study, we showed that YAP is upregulated and activated in NSCLC lung tissues and cell lines. Additionally, *YAP* knockdown inhibited lung cancer-cell proliferation, migration, and invasion and promoted apoptosis and senescence. Interestingly, metformin treatment induced similar effects on these biological processes. Therefore, we speculated that YAP inhibition might be an effect of metformin. As hypothesized, metformin treatment inhibited *YAP* expression and induced its phosphorylation, thereby reducing its nuclear translocation. Moreover, ectopic expression of *YAP* diminished the effect of metformin, whereas *YAP* silencing augmented it, indicating that YAP is a metformin target. We further confirmed the link between YAP and metformin in xenograft studies in nude mice, findings that co-treatment with metformin and VP, a YAP inhibitor, synergistically modulated YAP-specific biological processes. Collectively, our results suggested that YAP is involved in metformin-mediated biological processes ([Fig. 8](#f0040){ref-type="fig"}n).

Verteporfin (VP), a YAP specific inhibitor, can block the interaction between transcriptional coactivator YAP and transcriptional factor TEAD to repress YAP\'s function \[[@bb0225],[@bb0230]\]. During the past few years, several reports showed that VP is able to restrain cancer cell growth in some tumors, including retinoblastoma, endometrial and ovarian cancers \[[@bb0235], [@bb0240], [@bb0245]\]. However, the function and mechanism of VP inhibiting YAP activity in lung cancer were not yet clearly addressed. Our results showed that VP inhibited lung cancer cell growth, migration, invasion, EMT and induced cellular senescence and apoptosis meanwhile still had the ability to synergistically promote these effects of metformin on YAP function in lung cancer cells. The reason for the synergistical effect is that metformin decreases the YAP mRNA at transcriptional level, which then down regulates its target genes, Cyr61 and CTGF ([Fig. 3](#f0015){ref-type="fig"}). Of note, VP inhibits YAP function through restraining the interaction YAP and TEAD and then inhibits the expression of these YAP\'s target genes, that is represented function of YAP at protein level ([Fig. 7](#f0035){ref-type="fig"}). Therefore, the co-treatment with metformin and VP acted synergistically in the modulation of the biological processes mentioned above with reducing side effects ([Fig. 8](#f0040){ref-type="fig"}). Collectively, basing on the function and mechanism mentioned above of cotreatment of metformin and VP, we believe that cotreatment of these two drugs can better cure human lung cancers and hopefully, that will be applied to treat other human cancers.

There are two mechanisms associated with the anticancer effects of metformin: metformin lowers circulating insulin, which can bind to the insulin receptor highly expressed in cancer cells, thereby indirectly decreasing cell proliferation; and metformin directly activates AMPK and subsequently inhibits mammalian target of mTOR, leading to reduced cancer-cell proliferation \[[@bb0235], [@bb0240], [@bb0245]\]. Recent studies demonstrated that AMPK activation induces YAP phosphorylation and inhibits YAP transcriptional activity \[[@bb0180]\]. Additionally, LATS1/2 can be activated by an AMPK-dependent pathway to suppress YAP activity by phosphorylating YAP at S127 \[[@bb0185]\]. Specifically, AMPK phosphorylates angiomotin 1, which is associated with YAP, and increases its own stability, thereby leading to retention of YAP in the cytoplasm and promoting its phosphorylation by LATS1/2 \[[@bb0190]\]. AMPK can also directly phosphorylate YAP at S94 and inhibit YAP transcriptional activity by disrupting its interaction with TEAD. Moreover, AMPK directly phosphorylates YAP S61, reducing the expression of YAP target genes through an unknown mechanism \[[@bb0190]\]. Therefore, metformin might induce YAP phosphorylation to suppress its activity partly through an AMPK-dependent pathway. The effect of metformin could also be mediated independent of AMPK. A recent report showed that YAP is O-GlcNAcylated by an O-GlcNAc transferase, and that this modification prevents the interplay between YAP and LATS1 and leads to reduced YAP phosphorylation and enhanced transcriptional activity \[[@bb0195]\]. Accordingly, metformin might exert its effect by suppressing glucose-induced YAP O-GlcNAcylation \[[@bb0250]\]. Consistently, we found that metformin treatment induced YAP phosphorylation at S127 along with its nuclear exclusion. The expression of two YAP target genes, *CTGF* and *Cyr61*, was also reduced, further confirming that metformin suppressed YAP transcription functions. Furthermore, we found that metformin repressed YAP mRNA and protein expression, with downregulation of YAP protein expression partially attributed to the binding of phosphorylated YAP (S127) to 14-3-3, leading to its cytoplasmic retention, and subsequent degradation by the ubiquitin-proteasome pathway.

Our study confirmed that metformin decreased YAP luciferase activity, indicating that metformin downregulates YAP at the mRNA level. We hypothesized that metformin might be involved in the regulation of *YAP* transcription. To address our hypothesis, we isolated the core region of the *YAP* promoter. IRF-1 is important for the proliferation of human cancers, and IRF-1 silencing inhibits the growth of liver cancer cells. Additionally, IRF-1 mediates inflammation and increases pulmonary cathepsin S production \[[@bb0255]\]. Based on bioinformatics analyses, we found that the transcription factor IRF-1 might be involved in the attenuated *YAP* promoter activity mediated by metformin treatment. In order to further explore the mechanism of metformin attenuates YAP promoter activity by interfering with IRF-1 binding, we performed the UV-visible absorption spectral measurements and fluorescence polarization--based peptide displacement experiments, which are extracellular binding assay. Our result showed that metformin directly interfered with IRF-1 binding of YAP promoter not requirement of other cell molecules ([Fig. 4](#f0020){ref-type="fig"}d, e and [Supplementary Fig. 3](#f0055){ref-type="graphic"}m). Notably, our data showed that metformin depressed *YAP* promoter activity by interfering with the binding of IRF-1 and reducing *YAP* transcription. Our data showed that IRF-1 was able to induce *YAP* expression and that of its target genes, *CTGF* and *Cyr61*, after which upregulated YAP could then promote NSCLC initiation, progression, and metastasis. Collectively, our findings are consistent with the notion that YAP is a key factor in carcinogenesis. Therefore, these results showed that metformin downregulates YAP by competing with the transcription factor IRF-1 for binding on the *YAP* promoter, thereby inhibiting the growth of lung cancer.

In this study, we reported a novel function of metformin in regulating YAP through the transcription factor IRF-1 in NSCLC. In our model, metformin downregulates YAP by competing with IRF-1 for binding the *YAP* promoter in NSCLC cells ([Fig. 8](#f0040){ref-type="fig"}n). Our findings provide novel insights into the mechanism of MST-YAP-signaling regulation mediated by metformin in lung carcinogenesis. Therapeutically, metformin might be useful in the treatment of lung cancer. Additionally, because of the synergy exhibited between metformin and VP co-treatment, the combined use of metformin and VP could potentially reduce the side effects caused by their single use (at higher concentrations) and improve the quality of life of patients with lung cancer.

The following are the supplementary data related to this article.Supplementary Fig. 1A549 cells were transfected with siYAP-1 or siYAP-2 and then analyzed the expression of YAP.A549 cells were transfected with siYAP-1 or siYAP-2. a-c the mRNA and protein levels of YAP were analyzed by RT-PCR (a), immunoblotting assay (b) and RT-qPCR (c). d the cellular proliferation was analyzed by CCK8 assay. Results were presented as mean ± SD, and the error bars represent the SD of three independent experiments. (\*p \< 0.05, \*\*p \< 0.01, ANOVA with Bonferroni correction).Supplementary Fig. 1Supplementary Fig. 2Metformin significantly decreased the expression of YAP, CTGF and Cyr61 in a dose-and time-dependent manner in the NSCLC cells.a-d The A549 (a, c) and H1299 (b, d) cells were treated with indicated concentration of metformin for 60 h. The mRNA levels of YAP, CTGF and Cyr61 were analyzed by RT-PCR assay. e-h The A549 (e, g) and H1299 (f, h) cells were treated for indicated time of 10 mM metformin. The mRNA level of YAP, CTGF and Cyr61 were analyzed by RT-PCR assay.Supplementary Fig. 2Supplementary Fig. 3Metformin attenuates *YAP* promoter activity by interfering with IRF-1 binding in A549 cells.a the activities of different fragments of YAP promoter (pGL3-basic, pGL3-185, pGL3-131, pGL3-122, pGL3-54 and pGL3-185Δ) were measured by luciferase reporter gene assays in A549 cells. b-d A549 cells were transfected with siIRF-1-1 or siIRF-1-2. The mRNA and protein levels of IRF-1 were analyzed by RT-PCR (b), immunoblotting assay (c) and RT-qPCR (d). e the activities of pGL3-185 (−90\~+95) of YAP were measured by luciferase reporter gene assays in A549 cells with transfection with siIRF-1-1 or siIRF-1-2. f the mRNA level of YAP was analyzed by RT-qPCR assay. g A549 cells were transfected with indicated concentration of IRF-1 for 48 h. The expression of IRF-1 and YAP was analyzed by RT-qPCR. h A549 cells were transfected with 1 μg IRF-1 for indicated time. The expression of IRF-1 and YAP was analyzed by RT-qPCR at the indicated time. i, j A549 cells were transfected with 1 μg IRF-1 (i) or siIRF-1 (j) for 48 h. The expression of IRF-1, YAP, Cyr61 and CTGF was analyzed by RT-qPCR. k the diagram of the functional domain of IRF-1^(32)^. l the ChIP assays indicated that IRF-1 (1--120) could bind to *YAP* promoter. m the binding of metformin to YAP promotor was measured by an FP-based peptide displacement assay (K~disp~ of 10 ± 2.3 mM). n the microarray image of the SMM screened with fluorescently labeled IRF-1 response element within the *YAP* promoter. o the metformin hydrochloride obtained the excimer peak in the Q1 scanning of three stage quadrupole tandem mass spectrometry (*m*/*z* 130). Results were presented as mean ± SD, and the error bars represent the SD of three independent experiments. (\*p \< 0.05, \*\*p \< 0.01, ANOVA with Bonferroni correction).Supplementary Fig. 3Supplementary Fig. 4The activity of the YAP promoter and YAP expression were not regulated by E2F or IRF-2 in A549 cells.a-d A549 cells were transfected with E2F1 or siE2F1. a the activities of YAP promoter were measured by luciferase reporter gene assays. b, c the mRNA level of E2F1 and YAP was analyzed by RT-qPCR (b) and RT-PCR (c). d the protein level of E2F1 and YAP was analyzed by Western blot. e-h A549 cells were transfected with IRF-2 or siIRF-2. e the activities of YAP promoter were measured by luciferase reporter gene assays. f, g the mRNA level of IRF-2 and YAP was analyzed by RT-qPCR (f) and RT-PCR (g). h the protein level of IRF-2 and YAP was analyzed by Western blot. i, j A549 cells were treated with indicated concentration of metformin for 60 h. i the mRNA level of IRF-1 was analyzed by RT-qPCR. j the protein level of IRF-1 was analyzed by Western blot. Results were presented as mean ± SD, and the error bars represent the SD of three independent experiments. (\*p \< 0.05, \*\*p \< 0.01, NS (not significant; P \> 0.05), ANOVA with Bonferroni correction).Supplementary Fig. 4Supplementary Fig. 5Metformin inhibits cell migration growth and EMT in A549 cells.The A549 cells were treated with indicated concentration of metformin for 60 h. a Cellular migration ability was analyzed by cell scratch assay. b the mRNA level of E-cadherin and vimentin was analyzed by RT-qPCR. Results were presented as mean ± SD, and the error bars represent the SD of three independent experiments. (\*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, ANOVA with Bonferroni correction).Supplementary Fig. 5Supplementary Fig. 6Metformin interferes with YAP-mediated NSCLC initiation, progression, and metastasis not via AMPK dominated dependent manner.a-d A549 cells were transfected with YAP or YAPS127A, then treated with PBS or metformin 10 mM for 60 h. a the protein of Ki67 was analyzed by immunofluorescent staining. b the protein of active Caspase-3 was analyzed by immunoblotting assay c Cellular migration ability was analyzed by cell scratch assay. d Cellular invasion ability was analyzed by cell transwell assay. e,f A549 cells were transfected with YAP or si YAP, then treated with PBS or metformin 10 mM for 60 h. e the cellular proliferation was analyzed by CCK8 assay. f the Edu labeling cells were analyzed by immunofluorescent staining. Results were presented as mean ± SD, and the error bars represent the SD of three independent experiments. (\*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, ANOVA with Bonferroni correction).Supplementary Fig. 6Supplementary Fig. 7Metformin affects mitochondrial structure and function via inhibiting YAP and then restrains human cancer growth.a, b A549 cells were treated with control or siYAP. The proteins of mitochondrial cytC, cytosolic cytC (a), Bcl-2, Bcl-XL, Bax and PARP (b) were analyzed by immunoblotting assay. c A549 cells were treated with 10 mM metformin for 60 h. The proteins of mitochondrial cytC and cytosolic cytC were analyzed by immunoblotting assay. d, e A549 cells were treated with 10 mM metformin or co-treated with metformin and YAP. d the proteins of Yap, Bcl-2, Bcl-XL, Bax and PARP were analyzed by immunoblotting assay. e the oxidative stress in mitochondria was analyzed by MitoSox Red. f-j A549 cells were treated with 1 μM Mito-CP or co-treated with Mito-CP and YAP. f the oxidative stress in mitochondria was analyzed by MitoSox Red. g the cellular proliferation was analyzed by CCK8 assay. h the cellular growth was analyzed by MTT assay. i the protein of active Caspase-3 was analyzed by immunoblotting assay. j the protein of Annexin were analyzed by immunofluorescent staining. Results were presented as mean ± SD, and the error bars represent the SD of three independent experiments. (\*p \< 0.05, \*\*p \< 0.01, ANOVA with Bonferroni correction).Supplementary Fig. 7Supplementary Fig. 8Verteporfin synergistically augments the effects of metformin on YAP function in lung cancer cells.A549 cells were treated with metformin at 10 mM, verteporfin at 3.5 μM or cotreated with metformin and verteporfin for 60 h. a, b the proteins of YAP (a) and CTGF (b) were analyzed by immunofluorescent staining. c the mRNA level of YAP was analyzed by RT-qPCR. d the protein of Ki67 was analyzed by immunofluorescent staining. e the mRNA and protein levels of E-cadherin and Vimentin were analyzed by RT-PCR, immunoblotting and RT-qPCR assay. f Cellular migration ability was analyzed by cell scratch assay. Results were presented as mean ± SD, and the error bars represent the SD of three independent experiments. (\*\*p \< 0.01, NS (not significant; P \> 0.05), ANOVA with Bonferroni correction).Supplementary Fig. 8Supplementary Fig. 9Co-treatment with metformin and VP synergistically inhibited tumor growth and invasion related to YAP in vivo and in vitro.a the food intake of every three days indicated that the co-treatment of metformin and VP group was increased than the single metformin treatment group. b-f the xenograft tumor tissues were obtained from YAP over expression tumor-loaded mouse by treatment with metformin, verteporfin or co-treatment of metformin and verteporfin. The mRNA and protein levels of YAP, Cyr61 and CTGF were analyzed by RT-PCR (b), RT-qPCR (c, d) and immunoblotting assay (e). f the mRNA level of E-cadherin and Vimentin was analyzed by RT-qPCR. Results were presented as mean ± SD, and the error bars represent the SD of three independent experiments. (\*p \< 0.05, \*\*p \< 0.01, NS (not significant; P \> 0.05), ANOVA with Bonferroni correction).Supplementary Fig. 9
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